Increase in frequency of CXCR3-expressing B cells in peripheral blood under natalizumab. Frequencies of cells with the phenotype CD3−, CD19+, CD45RA+, HLA-DR+, CXCR3+ in PBMC from blood taken before or after the start of treatment with natalizumab were assessed by fluorescence flow cytometry in longitudinal blood samples from 7 patients with MS and expressed as a percentage of total lymphocytes defined by light scatter (\( ** p = 0.0075 \), paired, two-tailed t test).